机构投资者在Q3收入丰厚并提出了2025年的指导意见后,提升了布里斯托尔·迈尔斯·斯奎布的股份。 Institutional investors boosted Bristol Myers Squibb shares after strong Q3 earnings and raised 2025 guidance.

机构投资者包括Procyon Advisors,Nordea Investment Management和MGO One Seven在2025年第三季度增加了他们对布里斯托尔迈尔斯斯奎布的股权. Institutional investors including Procyon Advisors, Nordea Investment Management, and MGO One Seven increased their stakes in Bristol Myers Squibb during Q3 2025. 该公司在2025年10月30日报告Q3收入丰厚,有163美元EPS,粗略估计收入为11美元,收入122.2亿美元,比上一年增加2.8%。 The company reported strong Q3 earnings on October 30, 2025, with $1.63 EPS, beating estimates by $0.11, and $12.22 billion in revenue, up 2.8% year-over-year. 它将其2025年全年EPS指导提高到6.40-6.60美元。 It raised its 2025 full-year EPS guidance to $6.40–$6.60. 2026年1月16日股票交易约56.60美元, 市场上限为1 152.2亿美元, 股息收益为4.5%, The stock traded around $56.60 on January 16, 2026, with a market cap of $115.22 billion, a 4.5% dividend yield, and a consensus "Hold" rating.